Harrow earnings release, August 10, 2026
Exhibit
99.1
Harrow
Announces Second Quarter 2026 Financial Results
Second
Quarter 2026 and Selected Highlights:
NASHVILLE,
Tenn., August 10, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2026. The Company also posted its second-quarter Letter to Stockholders and corporate presentation in the “Investors” section of its website at harrow.com. The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business.
“We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability,” said Mark L. Baum, Chairman and
Chief Executive Officer of Harrow. “Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ®, advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1.
IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth – reinforcing our conviction that physician demand continues to strengthen across our portfolio.”
Baum continued, “As we enter the second half of the year, the business looks fundamentally different than it did just a few months ago:
IHEEZO’s pricing improvements are now in effect, IHEEZO’s channel inventories have normalized, VEVYE’s updated business rules have been fully implemented, BYOOVIZ has launched, and TYRVAYA is expected to join our portfolio later this year. Our commercial organization, which already expanded this year (and is now helping to fueling our growth), will increase further with the addition of experienced eye care sales professionals from Viatris. Together, these steps position us to convert the demand we’ve built into meaningful revenue growth and profitability. I believe Harrow has reached an important inflection point. The heavy lifting required to position the business for accelerated growth has largely been completed. The table is set. Now it’s about execution. Based on what we’re seeing across the business today, I remain confident in our ability to deliver our full-year guidance of $350 million to
$365 million in revenue and $80 million to $100 million in adjusted EBITDA.”
Key
Second Quarter Commercial Metrics
:
VEVYE:
IHEEZO:
TRIESENCE:
Business
Highlights
:
VEVYE
Expanded Coverage:
TYRVAYA
Acquisition:
-END-
BYOOVIZ
Launch:
Pipeline and Regulatory Highlights
:
Second
Quarter 2026 Financial Results
:
-END-
Conference
Call and Webcast
Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, August 11, 2026. Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, to access the call.
About
Harrow
Harrow,
Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on
LinkedIn.
Forward-Looking
Statements
Financial statements
Income Statement
For the Three Months Ended June 30, — Additional product-related revenue figures are reflected in the table below:
| For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2025 | |
|---|---|---|---|---|---|---|---|---|
| IHEEZO | 15,619,000 | 22.0% | 18,336,000 | 29.0% | 17,535,000 | 15.0% | 23,558,000 | 21.0% |
| VEVYE | 29,387,000 | 42.0% | 18,641,000 | 29.0% | 50,335,000 | 44.0% | 40,156,000 | 36.0% |
| Other branded products | 11,009,000 | 16.0% | 5,212,000 | 8.0% | 18,776,000 | 16.0% | 6,169,000 | 6.0% |
| Other revenues | 90,000 | 0.0% | 85,000 | 0.0% | 163,000 | 0.0% | 171,000 | 0.0% |
| Branded revenue, net | 56,105,000 | 79.0% | 42,274,000 | 66.0% | 86,809,000 | 76.0% | 70,054,000 | 63.0% |
| ImprimisRx revenue, net | 14,556,000 | 21.0% | 21,468,000 | 34.0% | 28,055,000 | 24.0% | 41,519,000 | 37.0% |
| Total revenues, net | 70,661,000 | 100.0% | 63,742,000 | 100.0% | 114,864,000 | 100.0% | 111,573,000 | 100.0% |
Income Statement
For the Three Months Ended June 30, — Selected financial highlights regarding GAAP operating results for the three months and six months ended June 30, 2026 and 2025 are as follows:
| For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Total revenues | 70,661,000 | 63,742,000 | 114,864,000 | 111,573,000 | |
| Cost of sales | 20,298,000 | 16,230,000 | 37,456,000 | 31,754,000 | |
| Gross profit | 50,363,000 | 47,512,000 | 77,408,000 | 79,819,000 | |
| Selling, general and administrative | 53,298,000 | 33,235,000 | 96,528,000 | 73,748,000 | |
| Research and development | 8,072,000 | 2,868,000 | 13,967,000 | 5,894,000 | |
| Total operating expenses | 61,370,000 | 36,103,000 | 110,495,000 | 79,642,000 | |
| (Loss) income from operations | -11,007,000 | 11,409,000 | -33,087,000 | 177,000 | |
| Total other expense, net | -6,263,000 | -6,414,000 | -11,760,000 | -12,962,000 | |
| Income tax expense | 25,000 | ||||
| Net (loss) income | -17,270,000 | 4,995,000 | -44,872,000 | -12,785,000 | |
| Net (loss) income per share: | Basic | -0.46 | 0.14 | -1.2 | -0.35 |
| Net (loss) income per share: | Diluted | -0.46 | 0.13 | -1.2 | -0.35 |
Income Statement
For the Three Months Ended June 30, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Total revenues | 70,661,000 | 63,742,000 | 114,864,000 | 111,573,000 | |
| Cost of sales | 20,298,000 | 16,230,000 | 37,456,000 | 31,754,000 | |
| Gross profit | 50,363,000 | 47,512,000 | 77,408,000 | 79,819,000 | |
| Selling, general and administrative | 53,298,000 | 33,235,000 | 96,528,000 | 73,748,000 | |
| Research and development | 8,072,000 | 2,868,000 | 13,967,000 | 5,894,000 | |
| Total operating expenses | 61,370,000 | 36,103,000 | 110,495,000 | 79,642,000 | |
| (Loss) income from operations | -11,007,000 | 11,409,000 | -33,087,000 | 177,000 | |
| Total other expense, net | -6,263,000 | -6,414,000 | -11,760,000 | -12,962,000 | |
| Income tax expense | 25,000 | ||||
| Net (loss) income attributable to Harrow, Inc. | -17,270,000 | 4,995,000 | -44,872,000 | -12,785,000 | |
| Net (loss) income per share: | Basic | -0.46 | 0.14 | -1.2 | -0.35 |
| Net (loss) income per share: | Diluted | -0.46 | 0.13 | -1.2 | -0.35 |
Balance Sheet
December 31, — CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| ASSETS | Cash and cash equivalents | 83,889,000 | 72,927,000 |
| ASSETS | All other current assets | 145,418,000 | 138,823,000 |
| ASSETS | Total current assets | 229,307,000 | 211,750,000 |
| ASSETS | All other assets | 187,509,000 | 187,732,000 |
| ASSETS | TOTAL ASSETS | 416,816,000 | 399,482,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Current liabilities | 102,171,000 | 96,302,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Loans payable, net of unamortized debt discount | 292,379,000 | 243,184,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | All other liabilities | 7,421,000 | 7,905,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL LIABILITIES | 401,971,000 | 347,391,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL STOCKHOLDERS’ EQUITY | 14,845,000 | 52,091,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 416,816,000 | 399,482,000 |
Full release
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward—looking statements.”
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, or complete pending acquisitions on terms and in the timeframe expected, or at all, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks... (truncated)e pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Such documents may be read free of charge on the SEC’s website at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contact:
Mike
Biega, VP of Investor Relations and Communications mbiega@harrowinc.com
617-913-8890
-END-
HARROW,
INC.